Prestige Consumer Healthcare Inc. (PBH) Financials
Key financial figures for Prestige Consumer Healthcare Inc. (Q2 2027).
Q2 FY2027 revenue rose 22.7% to $336.3 million on the Breathe Right and LaCorium acquisitions while organic revenue fell 1.6%, and the company trimmed its fiscal 2027 outlook to $1,280 to $1,290 million of revenue and $4.48 to $4.55 of adjusted diluted EPS. Revenue was $336.3 million versus $274.1 million a year earlier (+22.7%); excluding foreign currency and a $65.1 million contribution from the Breathe Right portfolio and LaCorium acquisitions, revenue decreased 1.6%, which the release ties to order timing pulled into Q1 and a decline in Clear Eyes. GAAP diluted EPS was $0.53 versus $0.86 and net income was $25.3 million versus $42.2 million; adjusted diluted EPS was $1.13 versus $1.07 a year earlier. On the outlook: Fiscal 2027 outlook updated: revenue $1,280 to $1,290 million (previously $1,290 to $1,315 million); organic revenue growth approximately flat (previously +1.0% to +3.0%); adjusted diluted EPS $4.48 to $4.55 (previously $4.55 to $4.65); adjusted free cash flow of $265 million or more (previously $270 million or more). Management attributed the update primarily to recent variability in Clear Eyes production at Pillar5, which it expects to reduce product availability and revenue in the second half, and said its outlook for the remainder of the portfolio is unchanged. Figures are for Q2 FY2027, as Prestige Consumer Healthcare Inc. reported them.
- Revenue
- $336M
- Net Income
- $25M
- EPS
- $0.53
- Total Assets
- $4.7B
- Operating Cash Flow
- $38M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2027 | $336M | $25M | $0.53 | 24% | $34M |
| Q1 FY2027 | $266M | $29M | $0.61 | 19.77% | $67M |
| Q4 FY2026 | $282M | $54M | $1.13 | 26.81% | $38M |
| Q3 FY2026 | $283M | $47M | $0.97 | 29.1% | $75M |
| Q2 FY2026 | $274M | $42M | $0.86 | 29.06% | $55M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2026 | $1.1B | $190M | $3.91 | 28.42% | $246M |
| FY2025 | $1.1B | $215M | $4.29 | 29.6% | $243M |
| FY2024 | $1.1B | $209M | $4.17 | 30.43% | $239M |
Frequently asked questions
What was Prestige Consumer Healthcare Inc.'s revenue last quarter?
Prestige Consumer Healthcare Inc. reported revenue of $336.3 million for Q2 FY2027, up 22.7% from the same period a year earlier.
Is Prestige Consumer Healthcare Inc. profitable?
Yes. Prestige Consumer Healthcare Inc. reported net income of $25.3 million for Q2 FY2027, a net margin of 7.52% on revenue.
How has Prestige Consumer Healthcare Inc.'s margin trended?
Operating margin was 24% in Q2 FY2027, compared with 29.06% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Prestige Consumer Healthcare Inc. generate?
Prestige Consumer Healthcare Inc. generated free cash flow of $34.2 million in Q2 FY2027, after capital expenditure.
Full income statement, balance sheet and cash flow for Prestige Consumer Healthcare Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.